Abstract
Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans.
Keywords:
Hamster; Henipavirus; Nipah; Single-dose; VSV; Vaccine.
Published by Elsevier B.V.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Cricetinae
-
Disease Models, Animal
-
Drug Carriers*
-
Henipavirus Infections / prevention & control*
-
Mesocricetus
-
Nipah Virus / genetics
-
Nipah Virus / immunology*
-
Survival Analysis
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / immunology
-
Vesiculovirus / genetics*
-
Viral Structural Proteins / genetics
-
Viral Structural Proteins / immunology
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / genetics
-
Viral Vaccines / immunology*
Substances
-
Drug Carriers
-
Vaccines, Synthetic
-
Viral Structural Proteins
-
Viral Vaccines